Keyphrases
High-dose Steroids
100%
Lymphocyte Profile
100%
Mediastinal Lymphadenopathy
100%
AE-IPF
100%
Retrospective Analysis
100%
Non-image Data
100%
COVID-19
100%
Positron Emission Tomography-computed Tomography (PET-CT)
100%
Pulmonary Nodule
100%
Benign Nodule
100%
Successful Treatment
100%
Automated Classification
100%
CT Images
75%
Ground-glass Opacity
50%
Malignant Nodules
50%
Conventional CT
50%
PET Image
50%
Delayed Phase
50%
Treatment Options
25%
Lung Biopsy
25%
Pulmonary Infiltrates
25%
Classification Accuracy
25%
Computed Tomography
25%
Subjective Judgments
25%
Functional Information
25%
Functional Traits
25%
Malignancy
25%
Severe Disabilities
25%
Anatomical Information
25%
Standardized Uptake Value
25%
Older Women
25%
Machine Learning Techniques
25%
Accuracy Rate
25%
Usual Interstitial Pneumonia
25%
Polymerase Chain Reaction Assay
25%
Methylprednisolone
25%
Bronchoscopy
25%
Classification Performance
25%
Dyspnea
25%
Classification Scheme
25%
Background Pattern
25%
Nodule Detection
25%
Shape Features
25%
Computed Tomography Examination
25%
Random Forest Algorithm
25%
Computed Tomography Images
25%
Artificial Intelligence Models
20%
Pandemic Situation
20%
New Scenario
20%
Clinician Feedback
20%
Medicine and Dentistry
Mediastinal Lymphadenopathy
100%
Bronchial Thermoplasty
100%
COVID-19
100%
Drug Megadose
100%
Idiopathic Pulmonary Fibrosis
100%
Respiratory Failure
100%
Asthma
100%
Airflow
50%
Ground Glass Opacity
50%
Forced Expiratory Volume
33%
Methylprednisolone
25%
Polymerase Chain Reaction
25%
Usual Interstitial Pneumonia
25%
Computer Assisted Tomography
25%
Pulmonary Infiltrate
25%
Dyspnea
25%
Severe Asthma
16%
Medical Record
16%
Bronchodilating Agent
16%
Cohort Study
16%
Intelligence
16%
Drug Therapy
16%
Immunology and Microbiology
Asthma
100%
Pet Animal
100%
Bronchial Thermoplasty
100%
Positron Emission Tomography-Computed Tomography
100%
Airflow
50%
Forced Expiratory Volume
33%
Decision Making
25%
Computer Assisted Tomography
25%
Random Forest
25%
Medical Record
16%
Bronchodilator
16%
Severe Asthma
16%